Arrow Mark Colorado Holdings LLC Nektar Therapeutics Transaction History

Arrow Mark Colorado Holdings LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $1.85 Million - $3.97 Million	-109,330 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $2.95 Million - $3.45 Million	-95,000 Reduced 46.49%	109,330 $3.89 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $1.36 Million - $1.99 Million	-43,000 Reduced 17.39%	204,330 $6.87 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $1.52 Million - $2.83 Million	50,000 Added 25.34%	247,330 $8.13 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $15,471 - $22,807	333 Added 0.17%	197,330 $12 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $36,075 - $81,471	-780 Reduced 0.39%	196,997 $9.62 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $13.4 Million - $25.3 Million	-233,000 Reduced 54.09%	197,777 $21 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $649,624 - $1.71 Million	-28,220 Reduced 6.15%	430,777 $25.7 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $8.17 Million - $11 Million	458,997	458,997 $11 Million

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $197M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.